0 Items
Select Page

Saint Louis Encephalitis Virus

Saint Louis Encephalitis virus (SLEV) is an emerging virus that causes encephalitis in humans. St Louis encephalitis (SLE) is an arthropod borne-disease transmitted by mosquitoes of the Culex species. In humans, SLEV infection is often asymptomatic and goes undiagnosed but, in some cases, neurological complications develop leading to coma and sometimes death.

The Native Antigen Company supply highly purified recombinant SLEV proteins to support SLEV research and assay development.

Saint Louis Encephalitis Virus Background

Saint Louis encephalitis virus (SLEV) is an enveloped, single-stranded, positive-sense RNA virus that belongs to the genus Flavivirus. It is a member of the Japanese encephalitis sero-complex of the family Flaviviridae, which also includes Japanese encephalitis virus, West Nile virus and Murray Valley encephalitis virus.

In nature, St. Louis Encephalitis virus is maintained in a cycle between mosquitoes of the Culex species and wild birds, which do not develop disease and act as amplifying hosts. Mosquito vectors can also transmit SLEV to humans and domestic animals, which act as dead-end hosts for the virus. SLEV is geographically widespread from Canada to South America, with most reported cases of human SLEV infection occurring in North America (Diaz, A).

In humans, SLEV infection causes the neuro-invasive disease known as St. Louis Encephalitis (SLE) but most cases are clinically asymptomatic and remain undiagnosed. A small percentage of patients present with symptoms of disease including headache, fever, nausea and general malaise. Some individuals recover but in rare cases, patients may further develop neurological complications including aseptic meningitis, encephalitis and coma, which can lead to death. Severity of disease and mortality due to SLEV infection is reported to increase with age, with approximately 90% of geriatric patients developing encephalitis (CDC).  

Currently, no antiviral therapy or licensed vaccine is available for the treatment and prevention of SLEV infection. Owing to the difficulty of isolating SLE from clinical samples, diagnosis of SLEV infection is commonly performed using serological methods to detect SLEV specific antibodies in serum and cerebrospinal fluid.

References

Diaz, A. et. al. (2018). Reemergence of St. Louis Encephalitis Virus in the Americas. Emerging Infectious Diseases24(12), 2150-2157. 

Centers of Disease Control and Prevention: St Louis Encephalitis.

Saint Louis Encephalitis Virus Antigens

The Native Antigen Company have developed recombinant Saint Louis Encephalitis virus proteins in our mammalian cell expression system. These antigens are suitable for use in assay development, vaccine research and as antigens for the preparation of specific antibodies.

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

The Immune Evasion Strategies of Lassa Fever Virus

In this blog, we outline the molecular pathogenesis of Lassa viral haemorrhagic fever and introduce our extended range of Lassa Fever virus antigens and antibodies.Viral haemorrhagic fevers Viral haemorrhagic fevers (VHF) are a diverse group of viral illnesses that...

Diphtheria toxin: The nuts and bolts

The Native Antigen Company manufactures high-quality Diphtheria toxin in its native format for a range of applications and is offering a 30% discount on this product for the remainder of 2019. In this blog we explain the structure, mechanism-of-action and applications...

Diagnosing HIV in resource-limited settings

In this blog, we discuss the need for improved point-of-care (PoC) diagnostics for HIV and present the virus's cellular mechanism to illustrate our new range of HIV antigens and antibodies. HIV in the developed world On June 5th 1981 in Los Angeles, California, 5...

Our Product Pipeline

If you’ve been following us on social media recently, you might have noticed that we’ve been releasing a lot of new antigens and antibodies. In this blog, we explain how we use the WHO R&D Blueprint to guide our product development and present some highlights from...

From Outbreak to Epidemic: A Short History of The Ebola Virus

In the first of a two-part series, we discuss the history of the Ebola virus up to the ongoing outbreak in the Democratic Republic of Congo, and why this disease has been so challenging to fight. The 2014/15 epidemic In the summer of 2014, the world watched as the...

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

9 + 12 =

Live Customer Feedback

Join our mailing list

* indicates required